Phase Ib Dose Escalation and Biomarker Study of MK-2206 in Combination With Standard Doses of Weekly Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in Advanced Breast Cancer.

Trial Profile

Phase Ib Dose Escalation and Biomarker Study of MK-2206 in Combination With Standard Doses of Weekly Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in Advanced Breast Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs MK 2206 (Primary) ; Paclitaxel
  • Indications Advanced breast cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 24 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 20 May 2014 Planned end date changed from 1 Sep 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top